| Abstract |
Chronic obstructive pulmonary disease (COPD) remains a significant area of unmet medical need. It is a progressive and irreversible lung disease that restricts breathing.
Daxas (Roflumilast) is a phosphodiesterase-4 (PDE4) inhibitor that is being developed to treat the underlying inflammation in COPD and related inflammatory diseases. It could be both the first PDE4 inhibitor and the first orally administered anti-inflammatory treatment for COPD patients. As a once-daily, non-steroidal anti-inflammatory treatment, Daxas� offers the opportunity for a new approach to the treatment of COPD. |
|
|
| Table of Contents |
|
| |
| Keywords |
| Roflumilast, COPD, Altana Pharma AG, Forest Laboratories, Pfizer, Tanabe Seiyaku Co Ltd |
|
| |
| Related reports |
|
|
